BIONET Corp. provides cord blood banking services in Taiwan and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$43.25|
|52 Week High||NT$35.15|
|52 Week Low||NT$51.90|
|1 Month Change||-3.03%|
|3 Month Change||0.23%|
|1 Year Change||5.75%|
|3 Year Change||33.08%|
|5 Year Change||35.16%|
|Change since IPO||204.61%|
Recent News & Updates
Should You Investigate BIONET Corp. (GTSM:1784) At NT$43.50?
BIONET Corp. ( GTSM:1784 ), is not the largest company out there, but it saw a significant share price rise of over 20...
If You Had Bought BIONET (GTSM:1784) Shares Three Years Ago You'd Have Earned 46% Returns
Investors can buy low cost index fund if they want to receive the average market return. But across the board there are...
|1784||TW Healthcare||TW Market|
Return vs Industry: 1784 exceeded the TW Healthcare industry which returned -5.5% over the past year.
Return vs Market: 1784 underperformed the TW Market which returned 33.6% over the past year.
Stable Share Price: 1784 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1784's weekly volatility (5%) has been stable over the past year.
About the Company
BIONET Corp. provides cord blood banking services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC + immune cells; and genetic testing services. It also provides stem anti-aging, rose stem rejuvenation, ultimate protection and repair, and ANIKINE series products.
BIONET Fundamentals Summary
|1784 fundamental statistics|
Is 1784 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1784 income statement (TTM)|
|Cost of Revenue||NT$428.21m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.66|
|Net Profit Margin||3.47%|
How did 1784 perform over the long term?See historical performance and comparison
0.4%Current Dividend Yield
Is BIONET undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1784 (NT$43.25) is trading above our estimate of fair value (NT$24.46)
Significantly Below Fair Value: 1784 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1784 is poor value based on its PE Ratio (65.5x) compared to the TW Healthcare industry average (18.2x).
PE vs Market: 1784 is poor value based on its PE Ratio (65.5x) compared to the TW market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1784's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1784's PB Ratio (1.9x) is in line with the TW Healthcare industry average.
How is BIONET forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIONET has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has BIONET performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1784 has high quality earnings.
Growing Profit Margin: 1784's current net profit margins (3.5%) are higher than last year (0.6%).
Past Earnings Growth Analysis
Earnings Trend: 1784's earnings have grown significantly by 43.6% per year over the past 5 years.
Accelerating Growth: 1784's earnings growth over the past year (629%) exceeds its 5-year average (43.6% per year).
Earnings vs Industry: 1784 earnings growth over the past year (629%) exceeded the Healthcare industry -2.8%.
Return on Equity
High ROE: 1784's Return on Equity (2%) is considered low.
How is BIONET's financial position?
Financial Position Analysis
Short Term Liabilities: 1784's short term assets (NT$822.4M) exceed its short term liabilities (NT$237.4M).
Long Term Liabilities: 1784's short term assets (NT$822.4M) exceed its long term liabilities (NT$215.2M).
Debt to Equity History and Analysis
Debt Level: 1784 is debt free.
Reducing Debt: 1784 has not had any debt for past 5 years.
Debt Coverage: 1784 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1784 has no debt, therefore coverage of interest payments is not a concern.
What is BIONET current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1784's dividend (0.42%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.93%).
High Dividend: 1784's dividend (0.42%) is low compared to the top 25% of dividend payers in the TW market (5.25%).
Stability and Growth of Payments
Stable Dividend: 1784 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.
Growing Dividend: 1784 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 1784 is not paying a notable dividend for the TW market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1784's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Tian Lai Liu has been President of BIONET Corp. since September 1, 2006. Tian Lai Liu serves as General Manager at Bionet Corp. Tian Lai Liu served as Franchise Manager at J&J Medical Taiwan and Supervisor...
Experienced Board: 1784's board of directors are seasoned and experienced ( 15.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BIONET Corp.'s employee growth, exchange listings and data sources
- Name: BIONET Corp.
- Ticker: 1784
- Exchange: TPEX
- Founded: 1999
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: NT$2.053b
- Shares outstanding: 47.48m
- Website: https://www.bionetcorp.com
- BIONET Corp.
- No.28, Xinhu 1st Road
- Lane 36
- Taipei City
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 08:32|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.